Cancer Statistics. Cancer Information Service NCC, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare)
Flexen J, Ghazali N, Lowe D et al (2012) Identifying appearance-related concerns in routine follow-up clinics following treatment for oral and oropharyngeal cancer. Br J Oral Maxillofac Surg 50:314–320
Article CAS PubMed Google Scholar
Sharpe L, Patel D, Clarke S (2011) The relationship between body image disturbance and distress in colorectal cancer patients with and without stomas. J Psychosom Res 70:395–402
McGarvey EL, Baum LD, Pinkerton RC et al (2001) Psychological sequelae and alopecia among women with cancer. Cancer Pract 9:283–289
Article CAS PubMed Google Scholar
Batchelor D (2001) Hair and cancer chemotherapy: consequences and nursing care—a literature study. Eur J Cancer Care 10:147–163
Hesketh PJ, Batchelor D, Golant M et al (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12:543–549
Lemieux J, Maunsell E, Provencher L (2008) Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 17:317–328
Dua P, Heiland MF, Kracen AC et al (2017) Cancer-related hair loss: a selective review of the alopecia research literature. Psychooncology 26:438–443
Boland V, Brady AM, Drury A (2020) The physical, psychological and social experiences of alopecia among women receiving chemotherapy: an integrative literature review. Eur J Oncol Nurs 49:101840
Kim IR, Cho J, Choi EK et al (2012) Perception, attitudes, preparedness and experience of chemotherapy-induced alopecia among breast cancer patients: a qualitative study. Asian Pac J Cancer Prev 13:1383–1388
Paterson C, Kozlovskaia M, Turner M et al (2021) Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review. J Cancer Surviv 15:14–28
Article CAS PubMed Google Scholar
Deutsch A, Leboeuf NR, Lacouture ME et al (2020) Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book 40:485–500
Geisler AN, Phillips GS, Barrios DM et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83:1255–1268
Article CAS PubMed PubMed Central Google Scholar
Bracarda S, Ruggeri EM, Monti M et al (2012) Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol 82:378–386
Chan JC, Lee YH, Liu CY et al (2019) A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res 27:e51
Haley AC, Calahan C, Gandhi M et al (2011) Skin care management in cancer patients: an evaluation of quality of life and tolerability. Support Care Cancer 19:545–554
Nozawa K, Shimizu C, Kakimoto M et al (2013) Quantitative assessment of appearance changes and related distress in cancer patients. Psychooncology 22:2140–2147
Sakai H, Koyama A, Tanaka K et al (2020) Psychosocial effects of appearance changes due to cancer treatment and needs for information and supportive care in Japanese cancer patients. Asia Pac J Clin Oncol 16:e185–e191
Fobair P, Stewart SL, Chang S et al (2006) Body image and sexual problems in young women with breast cancer. Psychooncology 15:579–594
Appearance Support Project for Cancer Patients, Tokyo Metropolitan Government Bureau of Public Health. https://www.hokeniryo.metro.tokyo.lg.jp/iryo/iryo_hoken/gan_portal/chiryou/apiaranncecare/apiaranncesiennjigyou.html
Okamoto T, Shimozuma K, Katsumata N et al (2003) Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan. Breast Cancer 10:204–213
留言 (0)